Polynovo Ltd (ASX: PNV) Share Price and News

Dr Elliott until recently, was Global Head, Strategic Portfolio Management at CSL Behring, a role that is responsible for governance oversight and business value delivery from a multi-billion-dollar capital expansion portfolio. Dr Elliott previously held Strategic Expansion and Quality Senior Director roles within CSL, was the Managing Director at IDT Australia and commenced her career at DBL Faulding. Dr Elliott has a track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Her worldwide experience in new facility delivery, production scale up, strategy, regulatory affairs and audit will be invaluable to PolyNovo as the company scales its operations globally. Dr Elliott was a member of the Risk committee.

Mr Lumsden has more than 20 years of experience locally and internationally. Mr Lumsden is currently Chief Executive Officer of Wellcom Worldwide Australasia, having previously held the roles of Group Chief Financial Officer and Group Chief Operating Officer. Prior to joining Wellcom, Mr Lumsden was a Senior Manager within the Audit and Assurance practice of PricewaterhouseCoopers. Mr Lumsden is the Chair of the Risk Committee.

Mr Hoare has expertise across multiple Life Sciences sectors. He is currently the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously he was Managing Director of Smith & Nephew (S&N) ANZ. He served as President of S&N's Asia-Pacific Advanced Wound Management (AWM) businesses for 5 years and was a member of the Global Executive Management (as one of three Regional Presidents). In his 24 years with Smith & Nephew, he held roles in marketing, divisional and general management. His career also included a senior role at Bristol-Myers Squibb, and as Vice Chair of the Board of Australia's medical device industry body, Medical Technology Association of Australia. Mr Hoare is a member of the Risk Committee.

Ms Donnelly has more than 30 years of local and international experience. She has been on the Board of the Institute of Patent and Trademark Attorneys of Australia for over a decade. Previously, Ms Emmanuel-Donnelly was Executive Manager of Business Development and Commercial at the CSIRO, was in-house IP Counsel for Unilever in the U.K., and practiced as a patent and trademark attorney for Wilson Gunn (U.K.), Davies Collison Cave and Griffith Hack. Ms Emmanuel Donnelly is member of the Risk Committee.

Mr Douglas has more than thirty-five years of experience in medical device technology, in digital health. He also has a decade of experience in public company governance, including audit, risk management, and compliance oversight. Mr Douglas had a number of strategy and operational roles before joining ResMed Inc. Australia (NYSE: RMD, ASX: RMD) in 2001. Since then, he has had various roles in the U.S. and Australia including Vice President Corporate Marketing, Vice President Operations and President and Chief Operating Officer from 2013 to 2023. ResMed is a global medical device and software applications company providing solutions to diagnose, treat and manage respiratory disorders and improve care in out-of-hospital settings. Mr Douglas is currently a member of the Board of Directors and Audit Committee for Globus Medical Inc. (NYSE: GMED), a global musculoskeletal medical technology company.

-

-

-

-

-

-